BUY Aurobindo Pharma — HSBC Securities, 07 Oct 2026

BUYAurobindo Pharma

Aurobindo Pharma share price target & all analyst calls

byHSBC SecuritiesHorizon: NA (inferred 1 year)7 Oct 2026via Zee Business (Live)

Entry₹1,696.2Inferred

Target₹1,955

Total upside +15.26%

Stop lossNot given

CMP₹1,6453h ago

Active-3.02%+18.84%upside left 12 mo left

Follow HSBC Securities for new calls(100% target hit, 14 closed calls)Get alerts Watch AUROPHARMA for new buy/sell callsGet alerts See 9 other Long-term calls on AUROPHARMA See 105 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 8 Oct, 7:54 pm IST

41 supporting14 neutral8 opposing

Supports the BUY call (41)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·7 Oct · yesterday

Aurobindo Pharma gets USFDA final approval for Perampanel tablets

NewsCnbc-Tv18·3 Oct · 5d ago

Aurobindo Pharma received final approval from the USFDA for Perampanel Tablets in multiple strengths.

BSE · Company Update·3 Oct · 5d ago

Aurobindo Pharma's subsidiary, A1 USA Inc, has acquired 100% ownership of A1 Biochem Labs LLC for USD 15.247 million to expand its contract research and development capabilities.

NSE · Acquisition·2 Oct · 6d ago

Aurobindo Pharma launches Adquey in US; Nuvama sees $300 million peak sales

NewsCnbc-Tv18·1 Oct · 1w ago

Neutral / worth noting (14)

These four pharma stocks will be reacting to important news updates today

NewsCnbc-Tv18·5 Oct · 3d ago

Aurobindo Pharma Ltd has announced the acquisition of a step-down subsidiary located in the USA.

BSE · Company Update·2 Oct · 6d ago

Aurobindo Pharma AGM results: ₹4 dividend confirmed, K. Nithyananda Reddy reappointed amid dissent

NewsGoogle News·20 Sept · 3w ago

Weighs against the BUY call (8)

1 advisor has an active short-term SELL call on this stock

Advisor consensus · adjacent horizon·6 Aug · 2mo ago

1 other SEBI-registered advisor has an active long-term SELL call on this stock

Advisor consensus · same horizon·27 Jul · 2mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aurobindo Pharma

All analyst calls on Aurobindo Pharma

More from HSBC Securities

Every call and its outcome